LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that it has received a Notice of Allowance from the?Chinese Patent Office?for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF).
News
MediciNova Added to the NASDAQ Biotechnology Index
LA JOLLA, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova … […]
News
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
LA JOLLA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that?MediciNova?… […]
News
MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive preclin… […]
